Helping Protect Lives
CIDALTEX® technology limits the risk of virus transmission and bacteria spread
Learn MoreCIDALTEX® technology enables bi-directional air flow decontamination by combining optimal performance filtration with effective pathogen inactivation
Learn MoreBioSerenity has integrated CIDALTEX® technology into disposable medical masks with high-performance filtration and pathogen decontamination
En savoir plusContact us to integrate CIDALTEX® technology into your products!
Learn MoreCIDALTEX® enables bi-directional air flow decontamination by combining optimal performance filtration and effective pathogen inactivation. It is equipped with a non-woven, highly efficient filtration layer (meltblown). These meltblown fibers are functionalized with a binding polymer and a safe decontaminant.
The CIDALTEX® meltblown fabric component ensures a high performance filtration of air flow: Particle Filtration Efficiency ≥ 94% (0.6μm particles), following the EN 149 requirement for FFP2 grade masks
CIDALTEX® technology purifies the air of indoor environments, and prevents the release of contaminated air into outdoor environments
CIDALTEX® is integrated into BioSerenity Medical Masks to protect from viruses and bacteria suspended in the ambient air or exhaled by the user.
CIDALTEX® technology has undergone rigorous tests, to measure the safety and efficiency of the filtration and decontamination layer, through accredited laboratories
|
BioSerenity has integrated CIDALTEX® technology onto masks initially certified as Personal Protective Equipment or as Medical Devices, to create disposable medical masks with optimal performance filtration and effective pathogen decontamination.
These innovative products protect both the user and their environment
(bi-directional filtration + inactivation of pathogens)
CIDALTEX® is a patented technology developed and industrialized by BioSerenity, a leading force of innovation in medical-grade, functionalized fabrics and textile-based wearables.
The technology originates from the initial work and results obtained during the H1N1 pandemic by an academic research team at INSERM, CNRS, and University of Lille (France). The methods have been recently adapted to meet the needs of the COVID-19 pandemic.
Do you have a project and would like to license the CIDALTEX® technology?
CIDALTEX® 2021 - All Rights Reserved